title: Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck.
abstract: Sixteen patients with end stage squamous cell carcinoma of the head and neck were admitted to a phase II study of alternating courses of cisplatinum (100 mg/m2) and VAC (vincristine 1.4 mg/m2, adriamycin 50 mg/m2, cyclophosphamide 750 mg/m2) given at three weekly intervals. Only two patients achieved a response (12 per cent). The median survival time was 62 days which is much the same as that of a similar group of patients who received no chemotherapy in a previous trial (70 days).
authors.affiliation: Royal Liverpool Hospital.
authors.forename: M Z
authors.initials: MZ
authors.lastname: Siodlak
authors.forename: P M
authors.initials: PM
authors.lastname: Stell
authors.forename: J A
authors.initials: JA
authors.lastname: Wilson
authors.forename: J A
authors.initials: JA
authors.lastname: Green
authors.forename: R S
authors.initials: RS
authors.lastname: Allison
authors.forename: D
authors.initials: D
authors.lastname: Adler
authors.forename: M
authors.initials: M
authors.lastname: Squadrelli-Saraceno
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin